Lyon Street Capital LLC Increases Position in Natus Medical Incorporated (BABY)

Lyon Street Capital LLC lifted its holdings in shares of Natus Medical Incorporated (NASDAQ:BABY) by 26.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 292,897 shares of the medical equipment provider’s stock after acquiring an additional 62,107 shares during the quarter. Natus Medical makes up 4.2% of Lyon Street Capital LLC’s portfolio, making the stock its 2nd biggest position. Lyon Street Capital LLC owned 0.94% of Natus Medical worth $10,984,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Koch Industries Inc. grew its stake in Natus Medical by 7,423.5% in the second quarter. Koch Industries Inc. now owns 462,472 shares of the medical equipment provider’s stock worth $450,000 after purchasing an additional 456,325 shares during the period. Hillcrest Asset Management LLC purchased a new stake in Natus Medical in the third quarter worth $8,966,000. Daruma Capital Management LLC grew its stake in Natus Medical by 13.1% in the second quarter. Daruma Capital Management LLC now owns 1,470,839 shares of the medical equipment provider’s stock worth $54,862,000 after purchasing an additional 169,890 shares during the period. Marshall Wace North America L.P. purchased a new stake in Natus Medical in the second quarter worth $5,832,000. Finally, Dimensional Fund Advisors LP grew its stake in Natus Medical by 10.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,552,938 shares of the medical equipment provider’s stock worth $57,924,000 after purchasing an additional 151,372 shares during the period. Institutional investors own 94.39% of the company’s stock.

In other news, Director William M. Moore sold 5,000 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $41.01, for a total value of $205,050.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Dong Chune Christopher Chung sold 12,642 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $42.91, for a total value of $542,468.22. Following the completion of the sale, the vice president now directly owns 141,414 shares in the company, valued at $6,068,074.74. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,042 shares of company stock worth $902,266. Insiders own 5.50% of the company’s stock.

Several brokerages recently weighed in on BABY. BidaskClub cut Natus Medical from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 24th. Zacks Investment Research raised Natus Medical from a “sell” rating to a “hold” rating in a research note on Friday, September 22nd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Natus Medical presently has a consensus rating of “Hold” and an average price target of $46.50.

Shares of Natus Medical Incorporated (NASDAQ BABY) opened at $38.80 on Wednesday. Natus Medical Incorporated has a 12 month low of $31.65 and a 12 month high of $43.60. The firm has a market capitalization of $1,227.47, a price-to-earnings ratio of 25.42 and a beta of 0.84. The company has a quick ratio of 3.36, a current ratio of 4.21 and a debt-to-equity ratio of 0.36.

Natus Medical (NASDAQ:BABY) last released its earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.02. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The firm had revenue of $122.60 million for the quarter, compared to analysts’ expectations of $122.41 million. During the same period in the prior year, the firm posted $0.39 earnings per share. The company’s quarterly revenue was up 34.9% on a year-over-year basis. analysts predict that Natus Medical Incorporated will post 1.74 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Lyon Street Capital LLC Increases Position in Natus Medical Incorporated (BABY)” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://stocknewstimes.com/2017/12/06/lyon-street-capital-llc-increases-position-in-natus-medical-incorporated-baby.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply